Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.004634%
Actinic keratosis23.01.06.0010.002317%Not Available
Angioedema23.04.01.001; Available
Anorectal disorder07.03.01.001--Not Available
Aphthous ulcer07.05.06.0020.003476%Not Available
Application site erythema23.03.06.005;; Available
Application site irritation12.07.01.003; Available
Application site oedema12.07.01.020; Available
Application site pain12.07.01.004; Available
Application site pruritus12.07.01.005;; Available
Application site rash23.03.13.008;; Available
Application site reaction12.07.01.006; Available
Application site ulcer12.07.01.007;; Available
Application site warmth08.02.01.029; Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.0010.009269%Not Available
Atrial fibrillation02.03.03.0020.003476%
Atrophic vulvovaginitis21.02.01.003--Not Available
Autoimmune hepatitis10.04.09.001; Available
Back pain15.03.04.0050.006952%
Basal cell carcinoma23.08.02.001; Available
Blindness17.17.01.003; Available
Blister23.03.01.001; Available
Blood glucose increased13.02.02.002--Not Available
Body temperature increased13.15.01.0010.002317%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages